Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.
Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K(+)-competitive, they probably bind to the enzyme in a different orientation. Compounds bearing a tertiary 4-(arylamino) substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines. We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C5, analogous to the 3-acylquinolines. Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K(+)-competitive inhibitors of K(+)-stimulated ATPase activity with Ki values down to 12 nM. Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously. However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.
Ife
R J
RJ
SmithKline Beecham Pharmaceuticals R & D, The Frythe, Welwyn, Herts, England.
Brown
T H
TH
Blurton
P
P
Keeling
D J
DJ
Leach
C A
CA
Meeson
M L
ML
Parsons
M E
ME
Theobald
C J
CJ
D000818:Animals; D004285:Dogs; D009682:Magnetic Resonance Spectroscopy; D054328:Proton Pump Inhibitors; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D011799:Quinazolines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D013270:Stomach / Q000201:enzymology*; D013329:Structure-Activity Relationship
D054328:Proton Pump Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; C013474:2,4-diaminoquinazoline